Applications for quantitative
measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients
with metastatic melanoma. Schreuer, Meersseman, Herrewegan, et al. Melanoma Res. 2015 Dec 3.
"Small fragments of cell-free DNA that are shed by
normal and tumor cells can be detected in the plasma of patients with advanced
melanoma. Quantitative measurement of BRAF V600 mutant DNA within the cell-free
DNA holds promise as a tumor-specific biomarker for diagnosis and therapeutic
monitoring in patients with BRAF V600 mutant melanoma. Allele-specific
quantitative PCR analysis for BRAF V600 E/E2/D/K/R/M mutations on DNA extracted
from 1 ml of plasma is currently under evaluation in a number of ongoing
prospective clinical studies. We report five patient cases that indicate the
potential applications and utility of quantitative measurements of BRAF V600
mutant cell-free tumor DNA as a diagnostic test and as a therapeutic monitoring
tool in stage IV melanoma patients treated with BRAF-targeted therapy or
immunotherapy. Finally, we offer novel insights into the dynamics of cell-free
tumor DNA in melanoma."
So this is the bandwagon many melanoma specialists are on at the moment as is evident by this article and the two recent posts noted below - all from differing sets of researchers! And, that's not a bad thing. My cynical self sees it as a race to the patented, FDA approved, money making test...for this bio-firm or for that set of researchers. My more hopeful self sees a potential method for minimally invasive, accurate diagnosis of the presence and type of melanoma an individual is dealing with, as well as a way to measure tumor burden and response to therapy.
Here's hoping! - c
No comments:
Post a Comment